Jade Biosciences Announces Pricing of Public Offering of Common Stock

Jade Biosciences (Nasdaq: JBIO), a clinical-stage biotech company focused on autoimmune diseases, announced the pricing of a public offering of 10 million shares at $15.00 per share, raising $150 million in gross proceeds. The offering is expected to close on June 5, 2026, with net proceeds to be used for clinical trials, preclinical studies, manufacturing, and R&D activities. Jefferies, TD Cowen, and UBS Investment Bank are serving as joint book-running managers.